FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2328551487> ?p ?o ?g. }

• W2328551487 abstract "This paper presents a summary of the evidence review group (ERG) report into the use of bevacizumab (Avastin®, Roche) in combination with a taxane for the treatment of untreated metastatic breast cancer (mBC). The main clinical effectiveness data were derived from a single, open-label randomised controlled trial (RCT) (E2100) that evaluated the addition of bevacizumab to weekly (q.w.) paclitaxel in patients with human epidermal growth factor receptor 2-negative mBC who had not previously received chemotherapy for advanced disease. This trial reported statistically significant increases in median progression-free survival (PFS) for the addition of bevacizumab (5.8-11.3 months). Median overall survival was not significantly different between the two groups; whether this is a true null finding or due to crossover between treatment arms cannot be established, as relevant data were not collected. The manufacturer reported that the addition of bevacizumab to paclitaxel q.w. therapy was associated with a significant improvement in quality of life, as measured by FACT-B (functional assessment of cancer therapy for breast cancer) scores. However, the ERG noted that these results were based on extreme imputed values, the removal of which led to non-significant differences in quality of life. The manufacturer conducted an indirect comparison. However, owing to methodological limitations and concerns about the validity and exchangeability of the included trials, the ERG did not consider the findings to be reliable. One additional relevant RCT [AVADO (Avastin and Docetaxel); BO17708] evaluating the addition of bevacizumab to docetaxel was excluded from the manufacturer's submission. This was summarised by the ERG. In terms of response rate and PFS, AVADO reported a markedly smaller benefit of adding bevacizumab to docetaxel than that reported for adding bevacizumab to q.w. paclitaxel in E2100. AVADO also reported no statistically significant effect of combination therapy versus docetaxel in terms of overall survival. The manufacturer developed a de novo economic model that considered patients with the same baseline characteristics as women in the E2100 trial. The model assessed BEV + PAC - bevacizumab 10 mg/kg every 2 weeks in combination with paclitaxel 90 mg/m2 weekly for 3 weeks followed by 1 week of rest; PAC q.w. - paclitaxel (monotherapy) 90 mg/m2 weekly for 3 weeks followed by 1 week of rest; DOC - docetaxel (monotherapy) 75 mg/m2 on day 1 every 21 days (considered current UK NHS clinical practice in the submission); and GEM + PAC - gemcitabine 1250 mg/m2 on days 1 and 8 plus paclitaxel 175 mg/m2 on day 1 every 21 days. Pairwise comparisons were made between BEV + PAC and PAC (using the E2100 trial), BEV + PAC and DOC, and BEV + PAC and GEM + PAC. Based on NHS list prices, the manufacturer's model estimated incremental cost-effectiveness ratios (ICERs) for BEV + PAC of £ 117,803, £ 115,059 and £ 105,777 per QALY gained, relative to PAC, DOC and GEM + PAC regimens, respectively. If the NHS Purchasing and Supply Agency prices for PAC with a 10-g cap on the cost per patient of BEV were used instead, the ICERs for BEV + PAC were estimated at £ 77,314, £ 57,753 and £ 60,101 per QALY, respectively. The submission suggested that the regimen of BEV + DOC is not cost-effective because it is considered less effective and more costly than BEV + PAC. Analysis by the ERG suggested that alternative assumptions can increase the ICERs further and, based on current prices, no plausible changes to the model assumptions will bring the ICERs for BEV + PAC lower." @default.
• W2328551487 created "2016-06-24" @default.
• W2328551487 creator A5010106280 @default.
• W2328551487 creator A5038214269 @default.
• W2328551487 creator A5053603345 @default.
• W2328551487 creator A5064000777 @default.
• W2328551487 creator A5064706698 @default.
• W2328551487 creator A5073128022 @default.
• W2328551487 date "2011-05-01" @default.
• W2328551487 modified "2023-09-27" @default.
• W2328551487 title "Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer" @default.
• W2328551487 cites W1536031281 @default.
• W2328551487 cites W1980766188 @default.
• W2328551487 cites W1997575819 @default.
• W2328551487 cites W2005947177 @default.
• W2328551487 cites W2006944422 @default.
• W2328551487 cites W2007259043 @default.
• W2328551487 cites W2015415893 @default.
• W2328551487 cites W2024991157 @default.
• W2328551487 cites W2053864737 @default.
• W2328551487 cites W2060513754 @default.
• W2328551487 cites W2070826508 @default.
• W2328551487 cites W2080725243 @default.
• W2328551487 cites W2091442233 @default.
• W2328551487 cites W2092586157 @default.
• W2328551487 cites W2120642503 @default.
• W2328551487 cites W2126275851 @default.
• W2328551487 cites W2128941584 @default.
• W2328551487 cites W2136791645 @default.
• W2328551487 cites W2159329940 @default.
• W2328551487 cites W2163003060 @default.
• W2328551487 cites W2225804955 @default.
• W2328551487 cites W2243738657 @default.
• W2328551487 cites W2247075085 @default.
• W2328551487 cites W2258266017 @default.
• W2328551487 cites W2322241559 @default.
• W2328551487 cites W2323432289 @default.
• W2328551487 cites W2591022134 @default.
• W2328551487 cites W2591450482 @default.
• W2328551487 cites W3135185800 @default.
• W2328551487 doi "https://doi.org/10.3310/hta15suppl1/01" @default.
• W2328551487 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21609648" @default.
• W2328551487 hasPublicationYear "2011" @default.
• W2328551487 type Work @default.
• W2328551487 sameAs 2328551487 @default.
• W2328551487 citedByCount "9" @default.
• W2328551487 countsByYear W23285514872012 @default.
• W2328551487 countsByYear W23285514872013 @default.
• W2328551487 countsByYear W23285514872014 @default.
• W2328551487 countsByYear W23285514872017 @default.
• W2328551487 countsByYear W23285514872018 @default.
• W2328551487 crossrefType "journal-article" @default.
• W2328551487 hasAuthorship W2328551487A5010106280 @default.
• W2328551487 hasAuthorship W2328551487A5038214269 @default.
• W2328551487 hasAuthorship W2328551487A5053603345 @default.
• W2328551487 hasAuthorship W2328551487A5064000777 @default.
• W2328551487 hasAuthorship W2328551487A5064706698 @default.
• W2328551487 hasAuthorship W2328551487A5073128022 @default.
• W2328551487 hasBestOaLocation W23285514871 @default.
• W2328551487 hasConcept C121608353 @default.
• W2328551487 hasConcept C126322002 @default.
• W2328551487 hasConcept C143998085 @default.
• W2328551487 hasConcept C168563851 @default.
• W2328551487 hasConcept C2775930923 @default.
• W2328551487 hasConcept C2776694085 @default.
• W2328551487 hasConcept C2777292972 @default.
• W2328551487 hasConcept C2777511904 @default.
• W2328551487 hasConcept C2777802072 @default.
• W2328551487 hasConcept C2780739268 @default.
• W2328551487 hasConcept C2781190966 @default.
• W2328551487 hasConcept C530470458 @default.
• W2328551487 hasConcept C71924100 @default.
• W2328551487 hasConceptScore W2328551487C121608353 @default.
• W2328551487 hasConceptScore W2328551487C126322002 @default.
• W2328551487 hasConceptScore W2328551487C143998085 @default.
• W2328551487 hasConceptScore W2328551487C168563851 @default.
• W2328551487 hasConceptScore W2328551487C2775930923 @default.
• W2328551487 hasConceptScore W2328551487C2776694085 @default.
• W2328551487 hasConceptScore W2328551487C2777292972 @default.
• W2328551487 hasConceptScore W2328551487C2777511904 @default.
• W2328551487 hasConceptScore W2328551487C2777802072 @default.
• W2328551487 hasConceptScore W2328551487C2780739268 @default.
• W2328551487 hasConceptScore W2328551487C2781190966 @default.
• W2328551487 hasConceptScore W2328551487C530470458 @default.
• W2328551487 hasConceptScore W2328551487C71924100 @default.
• W2328551487 hasFunder F4320334661 @default.
• W2328551487 hasIssue "Suppl. 1" @default.
• W2328551487 hasLocation W23285514871 @default.
• W2328551487 hasLocation W23285514872 @default.
• W2328551487 hasLocation W23285514873 @default.
• W2328551487 hasOpenAccess W2328551487 @default.
• W2328551487 hasPrimaryLocation W23285514871 @default.
• W2328551487 hasRelatedWork W181195935 @default.
• W2328551487 hasRelatedWork W1996698721 @default.
• W2328551487 hasRelatedWork W2077649377 @default.
• W2328551487 hasRelatedWork W2154590531 @default.
• W2328551487 hasRelatedWork W2315201629 @default.
• W2328551487 hasRelatedWork W2328551487 @default.
• W2328551487 hasRelatedWork W2468666928 @default.
• W2328551487 hasRelatedWork W2485409297 @default.

• next